Dr. Guillermo Garcia Manero and his colleagues published an abstract updating the active study results for oral azacitidine for low- and intermediate-risk MDS patients at the ASCO 2024 conference in June.
The ASTREON study's purpose is to evaluate the safety and efficacy of oral azacitidine in patients with low—to intermediate-risk MDS, as per the International Prognostic Scoring System Revised (IPSS-R). It is currently in phases 2 and 3, but it is not recruiting new patients at this time.
The study randomized patients to receive oral azacitidine at either 200 mg or 300 mg daily for 14 days per 28-day cycle, along with the best supportive care, including transfusions, treatment for anemia, and infection prevention in MDS patients.
In December 2023, the study showed similar adverse effects in 47 patients taking 200 mg and 300 mg of oral azacitidine; the most common were blood cell-related side effects and gastrointestinal concerns. 47 patients received at least one dose of oral azacitidine (200 mg: 24 patients, 300 mg: 23 patients)
The study's results support the continued evaluation of oral azacitidine in patients with low- to intermediate-risk MDS.
Additional research is needed to discover new treatment combinations and drug doses for patients with MDS. You can contribute to accelerating research by joining the HealthTree Community!
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in MDS.
Dr. Guillermo Garcia Manero and his colleagues published an abstract updating the active study results for oral azacitidine for low- and intermediate-risk MDS patients at the ASCO 2024 conference in June.
The ASTREON study's purpose is to evaluate the safety and efficacy of oral azacitidine in patients with low—to intermediate-risk MDS, as per the International Prognostic Scoring System Revised (IPSS-R). It is currently in phases 2 and 3, but it is not recruiting new patients at this time.
The study randomized patients to receive oral azacitidine at either 200 mg or 300 mg daily for 14 days per 28-day cycle, along with the best supportive care, including transfusions, treatment for anemia, and infection prevention in MDS patients.
In December 2023, the study showed similar adverse effects in 47 patients taking 200 mg and 300 mg of oral azacitidine; the most common were blood cell-related side effects and gastrointestinal concerns. 47 patients received at least one dose of oral azacitidine (200 mg: 24 patients, 300 mg: 23 patients)
The study's results support the continued evaluation of oral azacitidine in patients with low- to intermediate-risk MDS.
Additional research is needed to discover new treatment combinations and drug doses for patients with MDS. You can contribute to accelerating research by joining the HealthTree Community!
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in MDS.
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.